New drug combo shows promise for Hard-to-Treat blood cancers
NCT ID NCT02328014
First seen Nov 01, 2025 · Last updated Jun 05, 2026 · Updated 31 times
Summary
This early-stage study tested a combination of two drugs, acalabrutinib and ACP-319, in 40 people with B-cell cancers such as non-Hodgkin lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia. The goal was to check safety and how well the drugs work together. Participants had to have a confirmed diagnosis and be in relatively good health. The study is now complete.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Orange, California, 92868, United States
-
Research Site
Bethesda, Maryland, 20892, United States
-
Research Site
Rochester, New York, 14642, United States
-
Research Site
Portland, Oregon, 97239, United States
-
Research Site
Nashville, Tennessee, 37203, United States
-
Research Site
Austin, Texas, 78705, United States
-
Research Site
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.